{
    "title": [
        {
            "start": 1,
            "end": 94,
            "text": "Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea"
        },
        {
            "start": 2211,
            "end": 2304,
            "text": "Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea"
        }
    ],
    "abstract": [
        {
            "start": 2511,
            "end": 4170,
            "text": "Purpose Programmed death-1 blockade with pembrolizumab has shown promising activity in relapsed/refractory (R/R) extranodal natural killer/T-cell lymphoma (NKTCL), but studies are limited, with small patient numbers.Materials and MethodsThirteen institutes involved with the Consortium for Improving Survival of Lymphoma, a Korean lymphoma study group, collected the clinical data of 59 patients treated with pembrolizumab as salvage therapy between 2016 and 2022.ResultsThe median age of the patients was 60 years (range, 22 to 87 years), and 76.3% had advanced Ann Abor stage disease.Pembrolizumab was given to 35.6%, 40.7%, and 23.7% of the patients as second-, third-, and fourth-or higher-line chemotherapy, respectively.The overall response rate was 40.7%, with 28.8% having complete response.The estimated 2-year progression-free survival (PFS) and overall survival rates for all patients were 21.5% and 28.7%, respectively; for responders, the rates were 53.0% and 60.7%, respectively.Although not statistically significant, Eastern Cooperative Oncology Group performance status â‰¥ 2 (hazard ratio [HR], 1.91; 95% confidence interval [95% CI], 0.93 to 3.94; p=0.078) and stage III or IV disease (HR, 2.59; 95% CI, 0.96 to 6.96; p=0.060) were associated with a trend toward shorter PFS in multivariate analysis.Grade 3 or 4 adverse events (AEs) were noted in 12 patients (20.3%); neutropenia (10.2%), fatigue (6.8%), and pneumonitis (5.1%) were most common AEs.ConclusionIn conclusion, while pembrolizumab had a modest effect on patients with R/R NKTCL, it may be a useful salvage therapy for patients with localized disease and good performance status."
        }
    ],
    "authoraffiliation": [
        {
            "start": 126,
            "end": 287,
            "text": "Division of Hematology-Oncology\nDepartment of Internal Medicine\nSeoul National University Bundang Hospital\nSeoul National University College of Medicine\nSeongnam"
        },
        {
            "start": 303,
            "end": 381,
            "text": "Department of Internal Medicine\nChungbuk National University Hospital\nCheongju"
        },
        {
            "start": 399,
            "end": 507,
            "text": "Department of Internal Medicine\nHanyang University Guri Hospital\nHanyang University College of Medicine\nGuri"
        },
        {
            "start": 517,
            "end": 627,
            "text": "Division of Hematology-Oncology\nDepartment of Internal Medicine\nChung-Ang University College of Medicine\nSeoul"
        },
        {
            "start": 642,
            "end": 749,
            "text": "Division of Hematology-Oncology\nDepartment of Internal Medicine\nDong-A University College of Medicine\nBusan"
        },
        {
            "start": 765,
            "end": 853,
            "text": "Department of Oncology\nAsan Medical Center\nUniversity of Ulsan College of Medicine\nSeoul"
        },
        {
            "start": 869,
            "end": 929,
            "text": "Department of Internal Medicine\nDongsan Medical Center\nDaegu"
        },
        {
            "start": 945,
            "end": 1054,
            "text": "Department of Hematology and Oncology\nUlsan University Hospital\nUniversity of Ulsan College of Medicine\nUlsan"
        },
        {
            "start": 1070,
            "end": 1189,
            "text": "Department of Internal Medicine\nCancer Center Hospital\nInstitute of Radiological and Medical Sciences\nSeoulKorea, Korea"
        },
        {
            "start": 1191,
            "end": 1266,
            "text": "10 Department of Internal Medicine\nSeoul National University Hospital\nSeoul"
        },
        {
            "start": 1268,
            "end": 1364,
            "text": "11 Department of Internal Medicine\nBusan Paik Hospital\nInje University College of Medicine\nBusan"
        },
        {
            "start": 1366,
            "end": 1465,
            "text": "12 Department of Internal Medicine\nHaeundae Paik Hospital\nInje University College of Medicine\nBusan"
        },
        {
            "start": 1522,
            "end": 1657,
            "text": "Division of Hematology and Oncology\nDepartment of Medicine\nSamsung Medical Center\nSungkyunkwan University School of Medicine\nSeoulKorea"
        },
        {
            "start": 1672,
            "end": 1807,
            "text": "Division of Hematology and Oncology\nDepartment of Medicine\nSamsung Medical Center\nSungkyunkwan University School of Medicine\nSeoulKorea"
        },
        {
            "start": 1823,
            "end": 1984,
            "text": "Division of Hematology-Oncology\nDepartment of Internal Medicine\nSeoul National University Bundang Hospital\nSeoul National University College of Medicine\nSeongnam"
        },
        {
            "start": 2001,
            "end": 2209,
            "text": "Division of Hematology-Oncology\nDepartment of Internal Medicine\nSeoul National University Bundang Hospital\nSeoul National University College of Medicine\n173 Beon-gil, Bundang-gu82, 13620Gumi-ro, SeongnamKorea"
        }
    ],
    "author": [
        {
            "start": 1467,
            "end": 1477,
            "text": "Yougil Koh"
        },
        {
            "start": 1479,
            "end": 1490,
            "text": "Won Sik Lee"
        },
        {
            "start": 1492,
            "end": 1504,
            "text": "Sung Nam Lim"
        },
        {
            "start": 1506,
            "end": 1514,
            "text": "Eun Sang"
        },
        {
            "start": 1986,
            "end": 1998,
            "text": "Jeong-Ok Lee"
        }
    ],
    "doi": [
        {
            "start": 2365,
            "end": 2394,
            "text": "10.4143/crt.2023.1042Received"
        }
    ],
    "date": [
        {
            "start": 95,
            "end": 112,
            "text": "November 10, 2023"
        },
        {
            "start": 2316,
            "end": 2333,
            "text": "November 10, 2023"
        },
        {
            "start": 2395,
            "end": 2413,
            "text": "September 13, 2023"
        },
        {
            "start": 2423,
            "end": 2439,
            "text": "November 9, 2023"
        }
    ],
    "link": [
        {
            "start": 22420,
            "end": 22465,
            "text": "https://orcid.org/0000-0002-5835-7219Jeong-Ok"
        },
        {
            "start": 22472,
            "end": 22518,
            "text": "https://orcid.org/0000-0001-9402-6372Conflicts"
        }
    ]
}